CCTG Clinical Trials
Public Trial Select
Member Trial Select
Protecting Cancer Patients from COVID-19In the race to find new ways to prevent and treat COVID-19, CCTG has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients. More >> |
Recently Activated Trials
Member Links
CCTG Announces Initiation of IND.239CCTG has announced the commencement of a Phase II study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer. More >> |
Planned Trials
Committees Select
Group newsletter: CCTG Connection
January 20, 2021
 Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include: Read More |
 The CCTG Pharmacy Network is actively seeking pharmacy representation for a pharmacist representative for the Genitourinary Disease Site Committee and a pharmacist representative for the Steering Group from Quebec. Read More |
COVID-19 reminder to keep the CCTG updated on trial activitiesPublished: January 20, 2021Category: Group updates  For our Canadian member sites a COVID-19 reminder to keep the CCTG updated on trial activities at your site. Read More |
Seeking nominations for the 2021 CCTG Recognition AwardsPublished: January 20, 2021Category: Group updates  The Canadian Cancer Trials Group is seeking nominations for the 2021 Recognition Awards honouring individuals who have contributed significantly to the mission and activities of the Group. Read More |
CCTG is recruiting: Study Coordinators, Clinical Trial Assistants, and a Research AssociatePublished: January 20, 2021Category: Group updates  CCTG is hiring right now for several research positions; Clinical Trial Assistants, Study Coordinators and a Clinical Research Associate located at the CCTG Central Operations and Statistics Office at Queen's University in Kingston, Ontario. Read More |
January 06, 2021
|
|
 PR21 A Randomized Phase II Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease has been centrally activated. Read More |
 A look back at 2020, a pandemic year that saw tremendous achievements across the CCTG network This past year has been one of constant challenge within our group, network, country, and the world. Yet despite the disruptions to our daily lives and work, this year has also been one of immense accomplishment. Read More |
